Lilly Commits $4.5B to Expand Manufacturing for GLP-1 and Gene Therapies; InnoCare’s CDH17-Targeting ADC ICP-B208 Receives IND Approval
LTZ Therapeutics
Immunotherapy Developer
InnoCare
Innovative Drug Developer
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Pharmaceutical Research, Production, and Sales
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
The demand for drugs like GLP-1 poses challenges to the production capacity of pharmaceutical companies.
On May 6, Eli Lilly announced that it would invest an additional $4.5 billion in two production bases in Lebanon, Indiana, bringing the company's total capital expansion commitment in Indiana to over $21 billion since 2020.
CDH17 ADC is becoming increasingly competitive.
On May 7, InnoCare announced that the company's self-developed novel ADC drug ICP-B208 targeting CDH17 has been approved by the CDE to commence clinical research.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Yikang Pharmaceutical Plans to Invest 1 Billion Yuan in Building a Nucleic Acid Drug Base Project
On May 7, Yuhong Pharmaceutical announced that the company plans to invest in the construction of a nucleic acid drug base project in Hangzhou, with an estimated total investment of 1 billion yuan.
/ 02 /
Capital Information
1) LTZ Therapeutics Completes $38 Million Financing
On May 6, LTZ Therapeutics, focusing on novel immunotherapy, announced the completion of a $38 million financing round.
/ 03 /
Pharmaceutical News
1) InnoCare's CDH17 ADC Receives Clinical Approval
On May 7, InnoCare announced that the company's self-developed novel ADC drug targeting CDH17, ICP-B208, received CDE approval to commence clinical research.
2) Unblinding of Jiangsu Lianhuan Pharmaceutical Co., Ltd.'s LH-1801 Tablets Phase III Clinical Trial
On May 7, Jiangsu Lianhuan Pharmaceutical Co., Ltd. announced that the Phase III monotherapy clinical trial of the Class 1 new drug LH-1801 tablets has completed unblinding and obtained preliminary analysis results of the main data, with the primary endpoint meeting expectations. This drug is a novel SGLT-2 inhibitor indicated for Type 2 diabetes. The monotherapy trial showed that at 24 weeks of treatment, the changes in HbA1c from baseline in both the 20mg and 40mg LH-1801 tablet groups were superior to the placebo group (both P-values <0.0001). In the combination therapy trial, the efficacy of LH-1801 tablets combined with metformin was non-inferior to dapagliflozin combined with metformin.
3) Zhonghui Yuantong Respiratory Syncytial Virus mRNA Vaccine Receives Clinical Approval
On May 7, according to the CDE official website, Zhonghui Yuantong's Respiratory Syncytial Virus (RSV) mRNA vaccine received clinical approval for the prevention of lower respiratory tract disease (LRTD) caused by RSV infection.
/ 04 /
Overseas Pharmaceutical News
1) Eli Lilly Invests an Additional $4.5 Billion in Building a Factory
On May 6, Eli Lilly announced that it would invest an additional $4.5 billion in two production bases in Lebanon, Indiana, bringing the company's total capital expansion commitment in Indiana to over $21 billion since 2020.
PS: Welcome to scan the QR code below to add Amino Jun's WeChat for communication.
